Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma


Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
Slides from a presentation at ASH 2014 and a subsequent publication in The New England Journal of Medicine 2015 and transcribed comments from recent interviews with Craig Moskowitz, MD (1/6/15) and Stephen M Ansell, MD, PhD (1/20/15)
Ansell SM et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372(4):311-9. Abstract

Dr Moskowitz is Clinical Director of the Division of Hematologic Oncology, Attending Physician for Lymphoma and Adult BMT Services, Member of Memorial Sloan Kettering Cancer Center and Professor of Medicine at the Weill Medical College of Cornell University in New York, New York.

Dr Ansell is Professor of Medicine in the Division of Hematology at the Mayo Clinic in Rochester, Minnesota.